All guides
Every PeptideStat guide — research-backed breakdowns of peptide dosing, benefits, side effects and head-to-head comparisons.
Nasal peptide sprays are popular because they avoid needles, but intranasal delivery is peptide-specific. Regulated products and wellness sprays should not be treated as the same category.
Most peptides do not survive the gut well enough to work as ordinary pills. A few oral peptide medicines work because their chemistry, enhancer system, or local gut target is unusual.
Gut peptide claims range from approved oral GI drugs to research-only BPC-157 and KPV. The evidence depends on route, target and endpoint.
Skin peptides range from oral collagen and topical Matrixyl to Argireline, GHK-Cu, PDRN and glutathione. The evidence is useful but uneven.
Current guidance no longer treats every GLP-1 user the same before surgery. Risk depends on symptoms, dose escalation, procedure type and anesthesia plan.
A peptide COA can answer a narrow lab question. It cannot prove clinical evidence, safe human use, legal status, sterility or correct dosing by itself.
Abaloparatide is an FDA-approved PTHrP(1-34) analog peptide that builds bone in high-risk osteoporosis, backed by the ACTIVE and ATOM trials with clear duration and safety limits.
ACE-031 is not a classic peptide but an ActRIIB-Fc decoy receptor that traps myostatin and activin. Early trials showed muscle gains, but development was halted over vascular safety signals.
Adipotide is a research-only pro-apoptotic peptidomimetic that targeted fat-vessel prohibitin in animals but was abandoned in humans over kidney toxicity.
Albiglutide was an FDA- and EMA-approved once-weekly GLP-1 receptor agonist for type 2 diabetes that GSK voluntarily withdrew from the global market in 2018 for commercial reasons.
Amylin is an endogenous beta-cell hormone behind satiety and glucose control, but native amylin aggregates and is a research target rather than a consumer drug.
Antimicrobial peptides are a real area of drug research, but LL-37, KPV, melittin and related peptides sit at very different evidence and safety levels.
Argireline is a topical cosmetic hexapeptide marketed as topical Botox, with modest, mostly industry-funded wrinkle evidence and a major skin-permeation limitation.
Atosiban is an EU-approved oxytocin and vasopressin receptor antagonist peptide used intravenously as a short-term tocolytic to delay preterm labor.
Bivalirudin is an FDA-approved, hirudin-derived bivalent direct thrombin inhibitor used as a short-acting intravenous anticoagulant during percutaneous coronary intervention.
Buserelin is an approved GnRH agonist peptide (Suprefact) used for prostate cancer, endometriosis and IVF down-regulation, with strong hormone-suppression evidence and important safety limits.
Calcitonin is an approved calcitonin-receptor agonist peptide with label-backed bone uses, modest evidence and a malignancy-signal caution that shapes its modern role.
Carbetocin is an approved long-acting oxytocin analog peptide used to prevent postpartum hemorrhage, with a heat-stable formulation and label-backed evidence.
Cetrorelix is an FDA-approved GnRH antagonist peptide used in IVF to block premature LH surges without the early flare of GnRH agonists.
Colivelin is a synthetic ADNF-Humanin hybrid peptide with striking preclinical neuroprotection but no human trials and no established human dosing.
Cortexin is a low-molecular-weight cortical polypeptide drug marketed in Russia, with mostly Russian-language evidence and no FDA or EMA approval.
Davunetide is an investigational ADNP-derived octapeptide that stabilizes microtubules but failed a large progressive supranuclear palsy trial and is not approved for any use.
Degarelix is an FDA-approved GnRH antagonist peptide that rapidly suppresses testosterone in advanced prostate cancer without the initial hormone flare seen with agonists.
Desmopressin is an approved synthetic vasopressin V2 analog with antidiuretic and hemostatic uses, strong label evidence, and a central hyponatremia safety limit.
Dulaglutide is an FDA-approved once-weekly GLP-1 receptor agonist with strong type 2 diabetes and cardiovascular outcome evidence, plus a boxed thyroid warning.
Efpeglenatide is an investigational, exendin-based GLP-1 receptor agonist with positive AMPLITUDE-O cardiovascular and renal outcomes but no marketing approval.
Enfuvirtide is an FDA-approved 36-amino-acid HIV-1 fusion inhibitor for treatment-experienced patients, with strong trial evidence and notable injection-site safety limits.
Eptifibatide is an FDA-approved intravenous GP IIb/IIIa inhibitor peptide for acute coronary syndromes and PCI, with strong trial evidence and a bleeding-dominated safety profile.
Exenatide is the first FDA-approved GLP-1 receptor agonist, a synthetic exendin-4 peptide for type 2 diabetes with twice-daily and once-weekly products.
Ganirelix is an FDA-approved GnRH antagonist peptide used to block premature LH surges during controlled ovarian stimulation for IVF.
GHRP-2, or pralmorelin, is a ghrelin-receptor growth hormone secretagogue approved in Japan only as a GH-deficiency diagnostic, not as a consumer therapeutic.
Glucagon is an approved 29-amino-acid pancreatic hormone and glucagon-receptor agonist used as rescue therapy for severe hypoglycemia, available as injection and nasal powder.
Goserelin is an approved GnRH agonist peptide implant (Zoladex) with strong hormone-suppression evidence and important monitoring limits across oncology and gynecology.
HGH Fragment 176-191 is the C-terminal lipolytic fragment of growth hormone with animal data, but no convincing human fat-loss evidence.
Histrelin is an approved GnRH agonist peptide delivered as a 12-month subcutaneous implant, with label-backed evidence and important monitoring limits.
Humanin is a research-only mitochondrial-derived peptide with intriguing cytoprotective and longevity biology but no approved human use.
IGF-1 DES is a research-only truncated IGF-1 variant with reduced IGFBP binding, increased local potency and a very short half-life, studied only in cells and animals.
IGF-1 LR3 is a modified IGF-1 analogue built as a research reagent. Its reduced IGFBP binding raises potency in the lab, but human therapeutic data is essentially absent.
Lanreotide is an FDA-approved long-acting somatostatin analog peptide with strong label-backed evidence in acromegaly and neuroendocrine tumors.
Larazotide is an oral, gut-restricted tight-junction regulator that reached Phase 3 for celiac disease before the pivotal CeDLara trial was halted for futility.
Lixisenatide is a short-acting exendin-based GLP-1 receptor agonist approved for type 2 diabetes, with neutral cardiovascular data and clear safety limits.
Matrixyl is a topical collagen-signaling matrikine peptide (pal-KTTKS) backed by small cosmetic-grade wrinkle studies, not drug-level clinical evidence.
Melittin is the main cytolytic peptide of honeybee venom with promising preclinical antimicrobial and anticancer signals but no approved human use due to hemolysis and toxicity.
MGF is the IGF-1Ec splice variant linked to mechanical loading and muscle repair, but the evidence is largely cell and animal data, and no human therapeutic is approved.
Mitochondrial peptides are not one evidence tier. SS-31 has a narrow FDA-approved label, while MOTS-c, humanin and colivelin remain mostly preclinical or observational.
N-Acetyl Selank is a research-only, chemically stabilized analog of the Russian anxiolytic peptide Selank, with almost all evidence coming from the parent compound rather than the modified version.
N-Acetyl Semax is a research-only, chemically stabilized analog of Semax whose parent peptide has Russian-only approval and limited primary evidence.
Nafarelin is an approved intranasal GnRH agonist peptide marketed as Synarel for endometriosis and central precocious puberty, with clear hormone-suppression evidence and hypoestrogenic safety limits.
Nesiritide is a recombinant human BNP peptide that was FDA-approved for acute heart failure, found neutral in ASCEND-HF, and later discontinued.
P21 (P021) is a CNTF-derived neurotrophic peptide with promising rodent neurogenesis and Alzheimer's data but no human trials, approvals or established dosing.
Pasireotide is an approved multi-receptor somatostatin analog peptide for Cushing's disease and acromegaly, with strong label evidence and a notable hyperglycemia risk.
Pinealon is a research-only Khavinson tripeptide (Glu-Asp-Arg) with intriguing neuroprotection lab data but limited, low-quality human evidence.
Plecanatide is an FDA-approved 16-amino acid uroguanylin analog and guanylate cyclase-C agonist for chronic idiopathic constipation and IBS-C, with a boxed pediatric warning.
Secretin is an FDA-approved diagnostic peptide hormone used to stimulate pancreatic and gastrin secretion, not a wellness or performance compound.
Sincalide is the FDA-approved synthetic CCK-8 peptide used as a short-acting intravenous diagnostic to stimulate gallbladder contraction and pancreatic secretion.
SNAP-8 is a topical cosmetic peptide that mimics SNAP-25 to soften expression lines, but its strongest efficacy claims come from manufacturer data, not independent trials.
Teriparatide is an FDA-approved recombinant PTH(1-34) peptide that builds bone in high-fracture-risk osteoporosis, with strong trial evidence and a distinctive safety history.
Terlipressin is a vasopressin analog prodrug, FDA approved as Terlivaz for hepatorenal syndrome, with strong vasoconstrictor evidence and serious respiratory and ischemic safety limits.
Thymalin is a calf-thymus peptide bioregulator approved in Russia for immunocorrection, with aging and immune claims resting mostly on Russian-language studies.
Thymogen is a synthetic glutamyl-tryptophan dipeptide immunomodulator marketed in Russia but unapproved elsewhere, with limited rigorous human evidence.
Thymosin beta-4 is a real endogenous actin-binding peptide with genuine wound, corneal and cardiac repair research, but systemic injectable use remains research-only.
Thymulin is a zinc-dependent thymic nonapeptide with interesting immune and neuroendocrine biology but no approved human indication and no established human dosing.
Triptorelin is an approved long-acting GnRH agonist peptide with label-backed hormone-suppression uses, an early flare phase and important safety monitoring limits.
Tuftsin is a naturally occurring IgG-derived tetrapeptide that stimulates phagocytosis through neuropilin-1, but it remains research-only with no approved human dosing.
Vasopressin is an approved nonapeptide hormone used intravenously as an ICU vasopressor, with strong label evidence but narrow indications and real ischemic risk.
Vesugen is a research-only Khavinson tripeptide (Lys-Glu-Asp) with gene-expression and vascular claims but very limited primary human evidence and no regulatory approval.
Vilon is a research-only Lys-Glu dipeptide bioregulator with intriguing rodent and cell-culture data but no approved human indication or robust clinical trials.
VIP is a short-lived signaling peptide whose synthetic form, aviptadil, has mixed clinical evidence and several unproven off-label uses.
Ziconotide is an FDA-approved, intrathecal-only N-type calcium channel blocker derived from cone snail venom, with strong refractory-pain evidence and a narrow safety window.
Icatibant is a synthetic decapeptide medicine for acute hereditary angioedema attacks, with evidence focused on bradykinin-driven swelling and label-specific emergency limits.
Linaclotide is an oral 14-amino-acid peptide medicine with label-backed evidence for IBS-C and constipation, but its safety story depends on age, diarrhea risk and product-specific use.
Collagen peptides have more human evidence than many wellness peptides, but the realistic case is modest skin and joint support, not disease treatment or guaranteed anti-aging.
Leuprolide is an approved GnRH agonist peptide with product-specific labels, strong hormone-suppression evidence and important safety monitoring limits.
Octreotide is an approved somatostatin analog with evidence in acromegaly and neuroendocrine tumors, but it is not a general anti-aging or peptide-market protocol.
Teduglutide is an approved GLP-2 analog for short bowel syndrome with intestinal failure, but its evidence and safety rules are narrower than peptide-market summaries often suggest.
Follistatin 344 is usually marketed as a myostatin-blocking muscle peptide, but the meaningful human evidence comes from specialist gene-therapy studies, not retail vials.
Glutathione is a tripeptide with real antioxidant biology, but skin-lightening and injection claims need a careful split between oral, topical and IV evidence.
FOXO4-DRI is a senolytic research peptide with real mechanistic and animal data, but human anti-aging outcomes are not established.
Gonadorelin is native GnRH in drug form, but pulsatile medical use is very different from peptide-clinic testosterone or fertility claims.
Afamelanotide is an approved melanocortin implant for erythropoietic protoporphyria, not a general tanning peptide or sunscreen substitute.
PDRN is popular in skin and recovery marketing, but the evidence is uneven: human wound studies are stronger than topical anti-aging claims.
GLP-1 weight loss can include lean mass loss, but lean mass is not the same as pure muscle. Here is how to read the evidence without panic or marketing spin.
PEG-MGF is marketed for muscle growth and repair, but the evidence is mostly mechanistic, cell, animal and doping-detection literature rather than human outcome trials.
GH-axis peptides can raise growth hormone or IGF-1 biomarkers, but side effects, glucose effects, product quality and evidence gaps differ sharply by compound.
Ipamorelin can stimulate growth hormone release in human pharmacology studies, but that is not proof of anti-aging, fat-loss or muscle-gain outcomes.
Retatrutide is not FDA approved as of June 12, 2026. The evidence is promising, but the practical answer depends on phase 3 completion, FDA review and regulated labeling.
Cerebrolysin has more human clinical literature than many nootropic peptides, but the evidence is mixed and it is not FDA approved in the United States.
Dihexa has a real preclinical research story, but no published human outcome evidence that supports retail nootropic claims.
Mazdutide is a GLP-1/glucagon dual agonist with Chinese clinical trial data and China approval, but it is not a US-approved obesity drug.
Pramlintide is the approved amylin analog behind Symlin, but its weight-loss story is narrower than newer obesity-amylin marketing suggests.
Kisspeptin has real human reproductive-hormone research, but it should not be flattened into a testosterone booster or fertility shortcut.
Oxytocin is a real peptide hormone and prescription drug, but social-bonding nasal spray claims are much less settled than the marketing suggests.
Setmelanotide is an FDA-approved MC4R agonist for rare obesity indications, not a general weight-loss peptide.
GHRP-6 can stimulate growth hormone release in controlled studies, but that does not validate broad muscle, fat-loss or anti-aging claims.
TB-500 has a real thymosin beta-4 research trail behind it, but direct human recovery evidence for TB-500 protocols remains weak.
DSIP has old, small human sleep studies and a large unresolved mechanism problem. It should not be treated as an established sleep treatment.
Hexarelin has human endocrine pharmacology data, but that does not validate bodybuilding, anti-aging or unsupervised GH-boosting claims.
ARA-290 has human phase 2 neuropathy data, but the evidence is narrow and does not validate broad nerve-repair or recovery claims.
LL-37 is a human antimicrobial peptide with real wound-trial data, but online infection, gut, Lyme and immune claims often outrun the evidence.
Epitalon is a longevity-marketed tetrapeptide with cell and animal data, but human anti-aging outcomes and long-term safety remain unestablished.
Melanotan II has limited human tanning data, active online demand and serious regulator warnings. It is not an approved tanning drug.
KPV has coherent preclinical anti-inflammatory research, especially in gut and wound models, but human therapeutic evidence remains a major gap.
SS-31 is now best understood as elamipretide, the Forzinity drug approved for Barth syndrome, not as a general anti-aging mitochondrial peptide.
MOTS-c is a mitochondrial-derived peptide with interesting metabolic research, but consumer claims around fat loss, endurance and anti-aging outrun human evidence.
Thymosin alpha-1 has more human literature than many immune peptides, but the evidence is condition-specific and does not support broad immune-booster claims.
AOD-9604 has rodent lipolysis data and human safety papers, but its obesity drug program failed to show enough weight-loss efficacy.
Survodutide is a dual GLP-1/glucagon agonist with human obesity and MASH data, but it remains investigational and not FDA approved.
Selank has small human anxiety-disorder studies and mechanistic research, but U.S. medical claims and peptide-market dosing claims need careful limits.
Semax has regional human stroke literature and extensive ischemia-model research, but broad nootropic and focus claims need much stronger evidence.
Cagrilintide is an investigational amylin analog. The strongest interest is CagriSema, Novo Nordisk's cagrilintide plus semaglutide combination.
CJC-1295 has human GH and IGF-1 pharmacology data, but no approved indication and no robust outcome trials for anti-aging, recovery or body composition claims.
PT-141 is better understood as bremelanotide, an FDA-approved melanocortin agonist with narrow label limits and important nausea and blood-pressure warnings.
Tesamorelin has unusually strong evidence for a peptide-market compound, but the evidence is narrow: HIV-associated visceral abdominal fat, not general fat loss.
Our Ascension Peptides review checks real COA lots, purity numbers, catalog depth, shipping, support and why Ascension is our preferred research-peptide source.
Retatrutide hits three receptors at once. GLP-1 and GIP cut calorie intake; glucagon is thought to raise energy expenditure. Here's what the science actually shows.
Retatrutide's trial numbers are striking: about 24% average weight loss at 48 weeks in Phase 2, with Phase 3 topline data going higher. Here's what's verified — and what isn't.
Retatrutide's side effects are mostly gastrointestinal and dose-related, easing after dose escalation. Phase 3 data added a skin-sensitivity signal. Here's what trials actually report.
GLP-1, GLP1, GLP 1, glp1s, GLP-1 RA, GLP-1 agonist, GIP, DPP-4 — every GLP-1-related term, drug name, and abbreviation explained in one place.
A 2026 University of Pennsylvania study analyzed 400,000+ Reddit posts on GLP-1s. Patients are reporting menstrual changes, hot flashes, chills and fatigue — symptoms not fully captured in trials.
Amgen (MariTide), Sanofi, Boehringer Ingelheim (survodutide), Altimmune (pemvidutide) and Pfizer all have GLP-1 programs in development. Where each one stands in 2026, and which look closest to market.
GLP-1 is a 30-amino-acid hormone released by intestinal L-cells after meals. It lives about 2 minutes naturally; the drugs stretch that to days. This is the biology that makes the difference.
GLP-1 treatment is a long-term commitment, not a short course. What to expect at each stage — evaluation, titration, maintenance, plateau, and the discontinuation conversation.
Saxenda (liraglutide) was the first GLP-1 approved for weight management. Daily injection, ~8% average weight loss, and still a useful option when newer weekly drugs aren't accessible.
Patients on GLP-1s report reduced alcohol cravings, and new research suggests the drugs slow alcohol metabolism — pushing blood-alcohol higher on less drink.
'Microdosing' a GLP-1 means staying below the FDA-approved doses — often to save money or dodge side effects. There's no clinical evidence behind it, and most doctors don't recommend it.
GLP-1 weight loss is gradual, not dramatic — typical losses are 2–4 lbs in month 1, 10–15 lbs by month 3, and 15–25% body weight by 12–18 months. The realistic timeline, not the highlight reel.
Novo Nordisk pioneered the modern GLP-1 era with semaglutide and liraglutide. In 2026 the lineup is Ozempic, Wegovy, Rybelsus, Saxenda, oral Wegovy, and the Phase 3 CagriSema combination.
Retatrutide adds glucagon receptor activation on top of the GLP-1/GIP mechanism — Phase 2 weight loss exceeded every approved drug. Where the triple agonist pulls ahead, and where it's still unproven.
Eli Lilly leads the GLP-1 class on average weight loss with tirzepatide (Mounjaro / Zepbound) — and is bringing the first oral small-molecule GLP-1 (Foundayo) plus the triple-agonist retatrutide.
Five GLP-1 medications are FDA-approved for chronic weight management in 2026. Wegovy, Zepbound and Saxenda by injection; oral Wegovy and Foundayo by pill — with approval dates for each.
Amazon Pharmacy + One Medical now offer a full GLP-1 program with Wegovy, Zepbound, and oral GLP-1s. Cash pricing starts at $149/month — but third-party 'GLP-1' listings on Amazon are not the same product.
GLP-1s and SGLT2 inhibitors are the two newest first-line diabetes drug classes — and they're often confused. They work completely differently. How to tell them apart, and when each one wins.
You don't need a famous clinic to get a legitimate GLP-1 prescription. How to find a local provider, when in-person beats telehealth, and what to ask before paying.
Bacteriostatic water is sterile water with benzyl alcohol preservative. This guide explains what it is, when it is used, when not to use it, and how to handle it safely.
Compounded GLP-1s run $199–$349/month for the same active ingredient as Wegovy or Zepbound. The legal landscape shifted in 2024–2025 — what changed, and what 'compounded' really means.
GLP-1 weight-loss dosing follows a slow titration pattern. Every approved drug's dose schedule — Wegovy, Zepbound, Saxenda, oral Wegovy and Foundayo — with the titration tables prescribers follow.
GLP-1 receptor agonists mimic a gut hormone to slow digestion, suppress appetite and improve blood sugar. The mechanism, the full drug class, and why newer dual and triple agonists go further.
Mounjaro is a GLP-1 receptor agonist, but it's also a GIP agonist — a dual-action drug that outperforms single-receptor GLP-1s on weight loss. What that second target means in practice.
Ozempic and Wegovy both contain semaglutide. The difference is the label, dose target, indication and insurance logic.
Definitions for the peptide terms people run into: amino acids, residues, sequence notation, molecular weight, half-life, reconstitution, BAC water, GLP-1 and more.
Half-life explains how quickly a peptide level falls over time. This guide covers decay math, accumulation, steady state, peak/trough and common peptide examples.
How peptide reconstitution works: choosing the right diluent, calculating concentration, mixing gently, labeling the vial, storing it correctly, and avoiding contamination.
How to think about peptide storage: unopened versus reconstituted vials, refrigeration, room-temperature limits, travel, labeling, light and heat exposure, and when to discard.
Semaglutide is the GLP-1 receptor agonist behind Ozempic (diabetes), Wegovy (weight loss) and Rybelsus (oral diabetes). Same molecule, three brands, different doses and indications.
Semaglutide is the newer weekly GLP-1 and generally produces more weight loss. Liraglutide is older, daily and may still matter for access or tolerance.
Tirzepatide generally wins on average weight loss. Semaglutide has the broader GLP-1 evidence footprint. The practical decision comes down to results, track record and cost.
Tirzepatide is the approved practical option. Retatrutide is the stronger-looking pipeline triple agonist, but it remains investigational.
Peptides are short chains of amino acids linked by peptide bonds. This guide explains the chemistry, terminology and why peptide sequence matters.
Zepbound usually wins on average weight loss. Wegovy has important semaglutide-specific label strengths. The brand-by-brand breakdown shows where each one earns its place.
Cash-pay GLP-1 prices range from $129 to $1,400 a month for the same molecule. The real savings, ranked by total monthly cost.
List prices on GLP-1 drugs run $968–$1,400/month, but real out-of-pocket spans $0 to $1,400 depending on insurance, savings cards, and whether you go brand or compounded.
Manufacturer copay cards from Novo Nordisk and Lilly are the biggest GLP-1 savings lever — $25/month with commercial insurance. How each program works in 2026, and which 'coupons' to ignore.
Seven GLP-1 receptor agonists carry FDA approval in 2026 across diabetes and weight-management labels, with a deep pipeline behind them — brand names, doses and approval years for each.
A step-by-step safety protocol for prescribed subcutaneous peptide injections: clean setup, alcohol wiping, vial handling, site rotation, sharps disposal, and two-injection scenarios.
A broad guide to weight-loss peptides, from approved GLP-1 and dual-incretin medicines to investigational retatrutide, cagrilintide and other research compounds.
Ro's Body Program runs $145/month for the program plus the drug. What you get for that, how the intake works, and where it falls short of other telehealth GLP-1 options.
A practical hair-growth hub: which peptide and peptide-adjacent ingredients have real rationale, what is only cosmetic, and what still beats them for evidence.
BPC-157 and TB-500 are both marketed for recovery, but their evidence is mostly preclinical. Side by side, the real question is which one has even less human data.
The Bryan Johnson hair protocol: Blueprint peptide shampoo, peptide serum, laser cap, minoxidil, ingredient roles, and supporting research.
GHK-Cu has real skin and follicle biology behind it, but the hair-growth evidence is still mostly early-stage and ingredient-level.
Ipamorelin and sermorelin both stimulate growth hormone release, but they work through different receptors and have very different regulatory histories.
Peptide shampoo can support scalp care, but rinse-off contact time caps what it can do. How to judge peptide shampoos, their ingredients, and where the Blueprint option fits.
Sermorelin is a GHRH (growth-hormone-releasing hormone) analog — not a GLP-1, despite being searched alongside them. What it does to growth hormone, and where it stands legally.
Zepbound currently leads on average weight loss in trials. Wegovy has the best cardiovascular evidence. An honest head-to-head of every approved GLP-1 — with the trade-offs the marketing skips.
GLP-1 weight-loss drugs produce 8–21% average body-weight reduction in trials. The honest version weighs eligibility, results, cost, side effects, and the rebound after you stop.
GLP-1 side effects are mostly gastrointestinal and dose-related. Nausea hits 40–70% of patients early; serious events like pancreatitis stay rare. The full picture, sorted by how worried to be.
GLP-1 is a hormone your gut releases after eating. The agonist drugs amplify that effect — slowing digestion, blunting appetite and steadying blood sugar.
Twelve telehealth platforms now prescribe GLP-1 drugs online. Prices range from $129 to $1,400+ per month. What each one offers, what it charges, and the ones to skip.
How retatrutide dosing was structured in published trials — escalation schedules, the dose ranges studied, and why titration matters.
Retatrutide is an investigational triple agonist drawing major attention for weight loss. The Phase 2 numbers are striking — and still early-stage.
BPC-157 is marketed hard for recovery and tissue repair. The animal data is genuinely interesting; the human data is almost entirely absent.
The information on PeptideStat is for educational and research purposes only and is not medical advice. Many peptides discussed are research compounds not approved for human use. Always consult a qualified healthcare professional before making any health decisions. Articles may contain affiliate links — we may earn a commission at no extra cost to you.